Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Gustave Roussy, Cancer Campus, Grand Paris: Clinical Trials & FDA Approval Profile

Gustave Roussy, Cancer Campus, Grand Paris (Global / Institutional) sponsors 52 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 38 active protocols (25 recruiting now), 4 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)17.3%
Median Closed Enrollment vs National (145 pts)51 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Gustave Roussy, Cancer Campus, Grand Paris
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)52
Active Pipeline (Recruiting Now)38 (25)
Completed vs Stopped Early4 / 9 (17.3%)
Median Closed Actual Enrollment51 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Gustave Roussy, Cancer Campus, Grand Paris
Hospital Research SiteLocationShared Protocols
Gustave RoussyVillejuif, Île-de-France Region45
Institut BergoniéBordeaux10
Centre Antoine-LacassagneNice10

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Gustave Roussy, Cancer Campus, Grand Paris
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT03819101Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate CancerPhase IIIRECRUITING
NCT05692999Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority StudyPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Gustave Roussy, Cancer Campus, Grand Paris Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI